PO.MCB02.01 · 分子与细胞生物学

内皮细胞自噬抑制对肿瘤发生的影响

​Impacts of endothelial cell autophagy inhibition on tumorigenesis

海报缩略图:内皮细胞自噬抑制对肿瘤发生的影响
编号 4664 展板 13 时间 4/21 09:00–12:00 区域 Section 20 主讲 Nancy Leon-Rivera, BA
分会场 Cell Death Regulation and Therapeutic Resistance in Cancer
查看 PDF 下载 PDF 🔒 查看 / 下载完整 PDF 需登录并开通下载套餐 · 查看套餐 / 开通 AACR 官方页面

作者与单位 Authors & Affiliations

Nancy Esmeralda Leon-Rivera, Brayden Chin, Teresa Monkkonen

Biology, San Diego State University, San Diego, CA

摘要 Abstract

中文摘要
转移是癌症相关死亡的主要原因,而这一负担在缺乏激素受体表达的乳腺癌中尤为严重。这些患者的治疗选择有限且预后较差。内皮细胞是转移的重要调节者,因为它们控制血管完整性和循环肿瘤细胞向其他组织的迁移。自噬是一种保守的降解过程,可促进肿瘤细胞的代谢适应,抑制自噬正作为乳腺癌及其他癌症的靶向治疗进行测试。然而,自噬抑制对肿瘤血管系统和转移的影响仍知之甚少。为确定内皮细胞自噬如何影响乳腺肿瘤进展,我们生成了由Cdh5CreER血管内皮钙黏蛋白启动子驱动的内皮细胞特异性Atg12和Atg5敲除(ECKO)小鼠。在MMTV-PyMT肿瘤类器官的原位移植和与PyMT小鼠的遗传杂交中,Atg12 ECKO小鼠相比对照显示原发肿瘤生长延迟。中期Atg12 ECKO肿瘤表现出凋亡增加,而在终点时增殖和坏死无变化,表明内皮细胞自噬在癌症进展中期促进肿瘤细胞高效存活。尽管CD31+血管密度增加,Atg12 ECKO肿瘤却表现出HIF1-alpha升高,与血管功能受损和缺氧一致。在原发肿瘤手术切除后,Atg12 ECKO小鼠表现出更高的肿瘤复发和肺转移率,向未荷瘤小鼠尾静脉注射PyMT细胞证实了转移性生长增强。为测试这些效应是否具有肿瘤类型特异性,我们使用了大鼠胰岛素启动子-SV40大T抗原(RIP-Tag)胰腺神经内分泌肿瘤模型,该类肿瘤高度血管化且对抗血管生成治疗敏感。与PyMT的发现相反,早期或晚期内皮Atg12缺失均未改变原发肿瘤负荷或生存。然而,Atg12 ECKO小鼠表现出肝微转移增加,表明内皮自噬缺失的效应高度依赖于具体情境。这些结果凸显了内皮自噬在塑造肿瘤生长和转移中的情境依赖性作用,强调在癌症治疗的自噬抑制策略中需考虑限制转移变化的策略。
查看英文原文 English abstract
Metastasis is the leading cause of cancer related mortality, and this burden is particularly severe in breast cancers lacking hormone receptor expression. These patients have limited treatment options and poorer outcomes. Endothelial cells are important regulators of metastasis, as they control vascular integrity and migration of circulating tumor cells into other tissues. Inhibition of autophagy, a conserved degradative process which promotes metabolic adaptation in tumor cells, is being tested as a targeted therapy for breast and other cancers. However, the impact of autophagy inhibition on the tumor vasculature and metastasis is poorly understood. To determine how endothelial autophagy influences breast tumor progression, we generated endothelial cell specific Atg12 and Atg5 knockout (ECKO) mice driven by the Cdh5CreER vascular endothelial cadherin promoter. In orthotopic transplantation of MMTV-PyMT tumor organoids and genetic crosses to PyMT mice, Atg12 ECKO mice displayed delayed primary tumor growth compared to controls. Mid- stage Atg12 ECKO tumors exhibited increased apoptosis, whereas proliferation and necrosis were unchanged at endpoint, indicating that endothelial cell autophagy promotes efficient tumor cell survival during mid-stage cancer progression. Despite increased CD31 + vascular density, Atg12 ECKO tumors demonstrated elevated HIF1-alpha, consistent with impaired vascular function and hypoxia. Following surgical resection of primary tumors, Atg12 ECKO mice demonstrated higher rates of tumor recurrence and lung metastasis, and tail vein injection of PyMT cells into tumor naïve mice confirmed enhanced metastatic outgrowth. To test whether these effects were tumor type specific, we used the Rat insulin promoter-SV40 Large T antigen (RIP-Tag) model of pancreatic neuroendocrine tumors, which are highly vascular and sensitive to anti-angiogenic therapy. Neither early nor late endothelial deletion of Atg12 altered primary tumor burden or survival, in contrast to the PyMT findings. However, Atg12 ECKO mice displayed increased liver micrometastasis, indicating that the effects of endothelial autophagy loss are highly context specific. These results highlight the context dependent roles of endothelial autophagy in shaping tumor growth and metastasis, underscoring the need to consider strategies to limit changes to metastasis with autophagy inhibition strategies in cancer therapy.
利益披露 Disclosure
N. E. Leon-Rivera, None.. B. Chin, None.. T. Monkkonen, None.

← 返回 AACR 2026 检索